Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.
Identifieur interne : 001832 ( Main/Exploration ); précédent : 001831; suivant : 001833Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.
Auteurs : Sultan Ayoub Meo [Arabie saoudite] ; Syed Ziauddin A. Zaidi [Pakistan] ; Trisha Shang [États-Unis] ; Jennifer Y. Zhang [États-Unis] ; Thamir Al-Khlaiwi [Arabie saoudite] ; Ishfaq A. Bukhari [Arabie saoudite] ; Javed Akram [Pakistan] ; David C. Klonoff [États-Unis]Source :
- Journal of King Saud University. Science [ 2213-686X ] ; 2020.
Abstract
Objectives
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, also known as COVID-19 pandemic has caused an alarming situation worldwide. Since the first detection, in December 2019, there have been no effective drug therapy options for treating the SARS-CoV-2 pandemic. However, healthcare professionals are using chloroquine, hydroxychloroquine, remdesivir, convalescent plasma and some other options of treatments. This study aims to compare the biological, molecular, pharmacological, and clinical characteristics of these three treatment modalities for SARS-COV-2 infections, Chloroquine and Hydroxychloroquine, Convalescent Plasma, and Remdesivir.
Methods
A search was conducted in the "Institute of Science Information (ISI)-Web of Science, PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library databases, Scopus, and Google Scholar" for peer reviewed, published studies and clinical trials through July 30, 2020. The search was based on keywords "COVID-19" SARS-COV-2, chloroquine, hydroxychloroquine, convalescent plasma, remdesivir and treatment modalities.
Results
As of July 30, 2020, a total of 36,640 relevant documents were published. From them 672 peer reviewed, published articles, and clinical trials were screened. We selected 17 relevant published original articles and clinical trials: 05 for chloroquine and/or hydroxychloroquine with total sample size (n = 220), 05 for Remdesivir (n = 1,781), and 07 for Convalescent Plasma therapy (n = 398), with a combined total sample size (n = 2,399). Based on the available data, convalescent plasma therapy showed clinical advantages in SARS-COV-2 patients.
Conclusions
All three treatment modalities have both favorable and unfavorable characteristics, but none showed clear evidence of benefit for early outpatient disease or prophylaxis. Based on the current available data, convalescent plasma therapy appears to show clinical advantages for inpatient use. In the future, ongoing large sample size randomized controlled clinical trials may further clarify the comparative efficacy and safety of these three treatment classes, to conclusively determine whom to treat with which drug and when to treat them.
DOI: 10.1016/j.jksus.2020.09.002
PubMed: 32921965
PubMed Central: PMC7474813
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.</title><author><name sortKey="Meo, Sultan Ayoub" sort="Meo, Sultan Ayoub" uniqKey="Meo S" first="Sultan Ayoub" last="Meo">Sultan Ayoub Meo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Physiology, College of Medicine, King Saud University, Riyadh</wicri:regionArea><wicri:noRegion>Riyadh</wicri:noRegion></affiliation></author><author><name sortKey="Zaidi, Syed Ziauddin A" sort="Zaidi, Syed Ziauddin A" uniqKey="Zaidi S" first="Syed Ziauddin A" last="Zaidi">Syed Ziauddin A. Zaidi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology (Hematology), University of Health Sciences, Lahore, Pakistan.</nlm:affiliation><country xml:lang="fr">Pakistan</country><wicri:regionArea>Department of Pathology (Hematology), University of Health Sciences, Lahore</wicri:regionArea><wicri:noRegion>Lahore</wicri:noRegion></affiliation></author><author><name sortKey="Shang, Trisha" sort="Shang, Trisha" uniqKey="Shang T" first="Trisha" last="Shang">Trisha Shang</name><affiliation wicri:level="2"><nlm:affiliation>Diabetes Technology Society, Burlingame, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Diabetes Technology Society, Burlingame, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Zhang, Jennifer Y" sort="Zhang, Jennifer Y" uniqKey="Zhang J" first="Jennifer Y" last="Zhang">Jennifer Y. Zhang</name><affiliation wicri:level="2"><nlm:affiliation>Diabetes Technology Society, Burlingame, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Diabetes Technology Society, Burlingame, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Al Khlaiwi, Thamir" sort="Al Khlaiwi, Thamir" uniqKey="Al Khlaiwi T" first="Thamir" last="Al-Khlaiwi">Thamir Al-Khlaiwi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Physiology, College of Medicine, King Saud University, Riyadh</wicri:regionArea><wicri:noRegion>Riyadh</wicri:noRegion></affiliation></author><author><name sortKey="Bukhari, Ishfaq A" sort="Bukhari, Ishfaq A" uniqKey="Bukhari I" first="Ishfaq A" last="Bukhari">Ishfaq A. Bukhari</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Pharmacology, College of Medicine, King Saud University, Riyadh</wicri:regionArea><wicri:noRegion>Riyadh</wicri:noRegion></affiliation></author><author><name sortKey="Akram, Javed" sort="Akram, Javed" uniqKey="Akram J" first="Javed" last="Akram">Javed Akram</name><affiliation wicri:level="1"><nlm:affiliation>University of Health Sciences, Lahore, Pakistan.</nlm:affiliation><country xml:lang="fr">Pakistan</country><wicri:regionArea>University of Health Sciences, Lahore</wicri:regionArea><wicri:noRegion>Lahore</wicri:noRegion></affiliation></author><author><name sortKey="Klonoff, David C" sort="Klonoff, David C" uniqKey="Klonoff D" first="David C" last="Klonoff">David C. Klonoff</name><affiliation wicri:level="2"><nlm:affiliation>Diabetes Research Institute, Mills-Peninsula Medical Center San Mateo, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Diabetes Research Institute, Mills-Peninsula Medical Center San Mateo, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32921965</idno><idno type="pmid">32921965</idno><idno type="doi">10.1016/j.jksus.2020.09.002</idno><idno type="pmc">PMC7474813</idno><idno type="wicri:Area/Main/Corpus">000C33</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C33</idno><idno type="wicri:Area/Main/Curation">000C33</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000C33</idno><idno type="wicri:Area/Main/Exploration">000C33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.</title><author><name sortKey="Meo, Sultan Ayoub" sort="Meo, Sultan Ayoub" uniqKey="Meo S" first="Sultan Ayoub" last="Meo">Sultan Ayoub Meo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Physiology, College of Medicine, King Saud University, Riyadh</wicri:regionArea><wicri:noRegion>Riyadh</wicri:noRegion></affiliation></author><author><name sortKey="Zaidi, Syed Ziauddin A" sort="Zaidi, Syed Ziauddin A" uniqKey="Zaidi S" first="Syed Ziauddin A" last="Zaidi">Syed Ziauddin A. Zaidi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology (Hematology), University of Health Sciences, Lahore, Pakistan.</nlm:affiliation><country xml:lang="fr">Pakistan</country><wicri:regionArea>Department of Pathology (Hematology), University of Health Sciences, Lahore</wicri:regionArea><wicri:noRegion>Lahore</wicri:noRegion></affiliation></author><author><name sortKey="Shang, Trisha" sort="Shang, Trisha" uniqKey="Shang T" first="Trisha" last="Shang">Trisha Shang</name><affiliation wicri:level="2"><nlm:affiliation>Diabetes Technology Society, Burlingame, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Diabetes Technology Society, Burlingame, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Zhang, Jennifer Y" sort="Zhang, Jennifer Y" uniqKey="Zhang J" first="Jennifer Y" last="Zhang">Jennifer Y. Zhang</name><affiliation wicri:level="2"><nlm:affiliation>Diabetes Technology Society, Burlingame, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Diabetes Technology Society, Burlingame, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Al Khlaiwi, Thamir" sort="Al Khlaiwi, Thamir" uniqKey="Al Khlaiwi T" first="Thamir" last="Al-Khlaiwi">Thamir Al-Khlaiwi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Physiology, College of Medicine, King Saud University, Riyadh</wicri:regionArea><wicri:noRegion>Riyadh</wicri:noRegion></affiliation></author><author><name sortKey="Bukhari, Ishfaq A" sort="Bukhari, Ishfaq A" uniqKey="Bukhari I" first="Ishfaq A" last="Bukhari">Ishfaq A. Bukhari</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Pharmacology, College of Medicine, King Saud University, Riyadh</wicri:regionArea><wicri:noRegion>Riyadh</wicri:noRegion></affiliation></author><author><name sortKey="Akram, Javed" sort="Akram, Javed" uniqKey="Akram J" first="Javed" last="Akram">Javed Akram</name><affiliation wicri:level="1"><nlm:affiliation>University of Health Sciences, Lahore, Pakistan.</nlm:affiliation><country xml:lang="fr">Pakistan</country><wicri:regionArea>University of Health Sciences, Lahore</wicri:regionArea><wicri:noRegion>Lahore</wicri:noRegion></affiliation></author><author><name sortKey="Klonoff, David C" sort="Klonoff, David C" uniqKey="Klonoff D" first="David C" last="Klonoff">David C. Klonoff</name><affiliation wicri:level="2"><nlm:affiliation>Diabetes Research Institute, Mills-Peninsula Medical Center San Mateo, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Diabetes Research Institute, Mills-Peninsula Medical Center San Mateo, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Journal of King Saud University. Science</title><idno type="eISSN">2213-686X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>Objectives</b></p><p>The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, also known as COVID-19 pandemic has caused an alarming situation worldwide. Since the first detection, in December 2019, there have been no effective drug therapy options for treating the SARS-CoV-2 pandemic. However, healthcare professionals are using chloroquine, hydroxychloroquine, remdesivir, convalescent plasma and some other options of treatments. This study aims to compare the biological, molecular, pharmacological, and clinical characteristics of these three treatment modalities for SARS-COV-2 infections, Chloroquine and Hydroxychloroquine, Convalescent Plasma, and Remdesivir.</p></div><div type="abstract" xml:lang="en"><p><b>Methods</b></p><p>A search was conducted in the "Institute of Science Information (ISI)-Web of Science, PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library databases, Scopus, and Google Scholar" for peer reviewed, published studies and clinical trials through July 30, 2020. The search was based on keywords "COVID-19" SARS-COV-2, chloroquine, hydroxychloroquine, convalescent plasma, remdesivir and treatment modalities.</p></div><div type="abstract" xml:lang="en"><p><b>Results</b></p><p>As of July 30, 2020, a total of 36,640 relevant documents were published. From them 672 peer reviewed, published articles, and clinical trials were screened. We selected 17 relevant published original articles and clinical trials: 05 for chloroquine and/or hydroxychloroquine with total sample size (n = 220), 05 for Remdesivir (n = 1,781), and 07 for Convalescent Plasma therapy (n = 398), with a combined total sample size (n = 2,399). Based on the available data, convalescent plasma therapy showed clinical advantages in SARS-COV-2 patients.</p></div><div type="abstract" xml:lang="en"><p><b>Conclusions</b></p><p>All three treatment modalities have both favorable and unfavorable characteristics, but none showed clear evidence of benefit for early outpatient disease or prophylaxis. Based on the current available data, convalescent plasma therapy appears to show clinical advantages for inpatient use. In the future, ongoing large sample size randomized controlled clinical trials may further clarify the comparative efficacy and safety of these three treatment classes, to conclusively determine whom to treat with which drug and when to treat them.</p></div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32921965</PMID><DateRevised><Year>2021</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-686X</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of King Saud University. Science</Title><ISOAbbreviation>J King Saud Univ Sci</ISOAbbreviation></Journal><ArticleTitle>Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.</ArticleTitle><Pagination><MedlinePgn>3159-3166</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jksus.2020.09.002</ELocationID><Abstract><AbstractText Label="Objectives" NlmCategory="UNASSIGNED">The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, also known as COVID-19 pandemic has caused an alarming situation worldwide. Since the first detection, in December 2019, there have been no effective drug therapy options for treating the SARS-CoV-2 pandemic. However, healthcare professionals are using chloroquine, hydroxychloroquine, remdesivir, convalescent plasma and some other options of treatments. This study aims to compare the biological, molecular, pharmacological, and clinical characteristics of these three treatment modalities for SARS-COV-2 infections, Chloroquine and Hydroxychloroquine, Convalescent Plasma, and Remdesivir.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">A search was conducted in the "Institute of Science Information (ISI)-Web of Science, PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library databases, Scopus, and Google Scholar" for peer reviewed, published studies and clinical trials through July 30, 2020. The search was based on keywords "COVID-19" SARS-COV-2, chloroquine, hydroxychloroquine, convalescent plasma, remdesivir and treatment modalities.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">As of July 30, 2020, a total of 36,640 relevant documents were published. From them 672 peer reviewed, published articles, and clinical trials were screened. We selected 17 relevant published original articles and clinical trials: 05 for chloroquine and/or hydroxychloroquine with total sample size (n = 220), 05 for Remdesivir (n = 1,781), and 07 for Convalescent Plasma therapy (n = 398), with a combined total sample size (n = 2,399). Based on the available data, convalescent plasma therapy showed clinical advantages in SARS-COV-2 patients.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">All three treatment modalities have both favorable and unfavorable characteristics, but none showed clear evidence of benefit for early outpatient disease or prophylaxis. Based on the current available data, convalescent plasma therapy appears to show clinical advantages for inpatient use. In the future, ongoing large sample size randomized controlled clinical trials may further clarify the comparative efficacy and safety of these three treatment classes, to conclusively determine whom to treat with which drug and when to treat them.</AbstractText><CopyrightInformation>© 2020 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meo</LastName><ForeName>Sultan Ayoub</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaidi</LastName><ForeName>Syed Ziauddin A</ForeName><Initials>SZA</Initials><AffiliationInfo><Affiliation>Department of Pathology (Hematology), University of Health Sciences, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Trisha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Diabetes Technology Society, Burlingame, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jennifer Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Diabetes Technology Society, Burlingame, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Khlaiwi</LastName><ForeName>Thamir</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukhari</LastName><ForeName>Ishfaq A</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akram</LastName><ForeName>Javed</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Health Sciences, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klonoff</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Diabetes Research Institute, Mills-Peninsula Medical Center San Mateo, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Saudi Arabia</Country><MedlineTA>J King Saud Univ Sci</MedlineTA><NlmUniqueID>9886378</NlmUniqueID><ISSNLinking>1018-3647</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chloroquine</Keyword><Keyword MajorTopicYN="N">Convalescent Plasma</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Remdesivir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>08</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>14</Day><Hour>5</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32921965</ArticleId><ArticleId IdType="doi">10.1016/j.jksus.2020.09.002</ArticleId><ArticleId IdType="pii">S1018-3647(20)30269-X</ArticleId><ArticleId IdType="pmc">PMC7474813</ArticleId></ArticleIdList><pmc-dir>pmcsd</pmc-dir>
<ReferenceList><Reference><Citation>Circulation. 2020 Aug 4;142(5):513-515</Citation><ArticleIdList><ArticleId IdType="pubmed">32501756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670</Citation><ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Jun;178:104793</Citation><ArticleIdList><ArticleId IdType="pubmed">32283108</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation><ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 2007 Nov 1;176(9):886-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17626910</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation><ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation><ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1956 Oct;222(2):555-64</Citation><ArticleIdList><ArticleId IdType="pubmed">13367025</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Apher Sci. 2020 Oct;59(5):102875</Citation><ArticleIdList><ArticleId IdType="pubmed">32694043</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 2020 Jul;40(7):659-671</Citation><ArticleIdList><ArticleId IdType="pubmed">32446287</ArticleId></ArticleIdList></Reference><Reference><Citation>J King Saud Univ Sci. 2020 Jun;32(4):2495-2499</Citation><ArticleIdList><ArticleId IdType="pubmed">32292261</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Aug 4;324(5):460-470</Citation><ArticleIdList><ArticleId IdType="pubmed">32492084</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 May 12;323(18):1824-1836</Citation><ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab Syndr. 2020 Jul - Aug;14(4):641-648</Citation><ArticleIdList><ArticleId IdType="pubmed">32428865</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation><ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Negl Trop Dis. 2017 May 24;11(5):e0005602</Citation><ArticleIdList><ArticleId IdType="pubmed">28542194</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clin Proc. 2020 Jun;95(6):1213-1221</Citation><ArticleIdList><ArticleId IdType="pubmed">32359771</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Med. 2020 Jul;46(1):17-26</Citation><ArticleIdList><ArticleId IdType="pubmed">32319538</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Cent Sci. 2020 May 27;6(5):672-683</Citation><ArticleIdList><ArticleId IdType="pubmed">32483554</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2019 Sep;169:104541</Citation><ArticleIdList><ArticleId IdType="pubmed">31233808</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Invest Clin. 2020;72(3):159-164</Citation><ArticleIdList><ArticleId IdType="pubmed">32584322</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Apr 28;323(16):1582-1589</Citation><ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId></ArticleIdList></Reference><Reference><Citation>Interdiscip Perspect Infect Dis. 2015;2015:346853</Citation><ArticleIdList><ArticleId IdType="pubmed">26357512</ArticleId></ArticleIdList></Reference><Reference><Citation>Haematologica. 2020 Jul 23;105(12):2834-2840</Citation><ArticleIdList><ArticleId IdType="pubmed">33256382</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1827-1837</Citation><ArticleIdList><ArticleId IdType="pubmed">32459919</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res. 2020 Aug;158:104899</Citation><ArticleIdList><ArticleId IdType="pubmed">32407959</ArticleId></ArticleIdList></Reference><Reference><Citation>Open Forum Infect Dis. 2020 Apr 15;7(4):ofaa130</Citation><ArticleIdList><ArticleId IdType="pubmed">32363212</ArticleId></ArticleIdList></Reference><Reference><Citation>J Korean Med Sci. 2020 May 11;35(18):e176</Citation><ArticleIdList><ArticleId IdType="pubmed">32383371</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Drugs Ther. 2019 Feb;33(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">30635818</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan Medicinhist Arbog. 2016;44:9-30</Citation><ArticleIdList><ArticleId IdType="pubmed">29737660</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2012-2019</Citation><ArticleIdList><ArticleId IdType="pubmed">32141570</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation><ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Metab Dispos. 2003 Jun;31(6):748-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12756207</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19188392</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation><ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496</Citation><ArticleIdList><ArticleId IdType="pubmed">32253318</ArticleId></ArticleIdList></Reference><Reference><Citation>Autoimmun Rev. 2020 Jul;19(7):102554</Citation><ArticleIdList><ArticleId IdType="pubmed">32380316</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Electrophysiol. 2020 Aug;31(8):1904-1907</Citation><ArticleIdList><ArticleId IdType="pubmed">32485061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Arabie saoudite</li><li>Pakistan</li><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="Arabie saoudite"><noRegion><name sortKey="Meo, Sultan Ayoub" sort="Meo, Sultan Ayoub" uniqKey="Meo S" first="Sultan Ayoub" last="Meo">Sultan Ayoub Meo</name></noRegion><name sortKey="Al Khlaiwi, Thamir" sort="Al Khlaiwi, Thamir" uniqKey="Al Khlaiwi T" first="Thamir" last="Al-Khlaiwi">Thamir Al-Khlaiwi</name><name sortKey="Bukhari, Ishfaq A" sort="Bukhari, Ishfaq A" uniqKey="Bukhari I" first="Ishfaq A" last="Bukhari">Ishfaq A. Bukhari</name></country><country name="Pakistan"><noRegion><name sortKey="Zaidi, Syed Ziauddin A" sort="Zaidi, Syed Ziauddin A" uniqKey="Zaidi S" first="Syed Ziauddin A" last="Zaidi">Syed Ziauddin A. Zaidi</name></noRegion><name sortKey="Akram, Javed" sort="Akram, Javed" uniqKey="Akram J" first="Javed" last="Akram">Javed Akram</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Shang, Trisha" sort="Shang, Trisha" uniqKey="Shang T" first="Trisha" last="Shang">Trisha Shang</name></region><name sortKey="Klonoff, David C" sort="Klonoff, David C" uniqKey="Klonoff D" first="David C" last="Klonoff">David C. Klonoff</name><name sortKey="Zhang, Jennifer Y" sort="Zhang, Jennifer Y" uniqKey="Zhang J" first="Jennifer Y" last="Zhang">Jennifer Y. Zhang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001832 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001832 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32921965
|texte= Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32921965" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |